STOCK TITAN

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags

KalVista Pharmaceuticals (NASDAQ: KALV) announced that its compensation committee has granted stock options to twelve newly-hired employees. The inducement grants total 78,000 shares of common stock with an exercise price of $10.61 per share, matching the closing price on November 1, 2024. The options vest over four years, with 25% vesting after one year and the remainder vesting monthly over three years, contingent on continued employment. These 10-year term options were granted under KalVista's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

KalVista Pharmaceuticals (NASDAQ: KALV) ha annunciato che il suo comitato per la compensazione ha concesso opzioni su azioni a dodici nuovi assunti. Le concessioni di indennizzo ammontano a 78.000 azioni di azioni ordinarie con un prezzo di esercizio di 10,61 $ per azione, corrispondente al prezzo di chiusura del 1 novembre 2024. Le opzioni maturano nell'arco di quattro anni, con il 25% che matura dopo un anno e il restante che matura mensilmente per tre anni, a condizione di un'occupazione continua. Queste opzioni con termine di 10 anni sono state concesse secondo il Piano di Incentivazione Equity di KalVista in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).

KalVista Pharmaceuticals (NASDAQ: KALV) anunció que su comité de compensación ha otorgado opciones sobre acciones a doce empleados recién contratados. Las concesiones de inducimiento suman 78,000 acciones de acciones comunes con un precio de ejercicio de $10.61 por acción, coincidiendo con el precio de cierre del 1 de noviembre de 2024. Las opciones se consolidan durante cuatro años, con el 25% consolidándose después de un año y el resto mensualmente durante tres años, condicionado a la continuidad del empleo. Estas opciones de 10 años se otorgaron bajo el Plan de Incentivo de Equidad de Inducción de KalVista de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4).

KalVista Pharmaceuticals (NASDAQ: KALV)는 보상 위원회가 신규 채용된 12명에게 주식 옵션을 부여했다고 발표했습니다. 유인 보상 총합은 78,000주의 보통주로, 주당 행사가격은 $10.61입니다. 이는 2024년 11월 1일의 종가와 일치합니다. 옵션은 4년 동안 분할 지급되며, 1년 후 25%가 지급되고 나머지는 3년 동안 매달 지급됩니다. 계속 근무하는 조건이 있습니다. 이 10년 기간의 옵션은 Nasdaq 상장 규칙 5635(c)(4)에 따라 KalVista의 유인 자본 인센티브 계획에 따라 부여되었습니다.

KalVista Pharmaceuticals (NASDAQ: KALV) a annoncé que son comité de rémunération a accordé des options d'achat d'actions à douze nouveaux employés. Les attributions incitatives totalisent 78 000 actions ordinaires avec un prix d'exercice de 10,61 $ par action, correspondant au prix de clôture du 1er novembre 2024. Les options s'acquièrent sur quatre ans, avec 25 % qui s'acquièrent après un an et le reste qui s'acquiert mensuellement pendant trois ans, sous réserve d'une poursuite de l'emploi. Ces options à terme de 10 ans ont été accordées dans le cadre du Plan d'incitation en actions de KalVista conformément à la règle d'inscription Nasdaq 5635(c)(4).

KalVista Pharmaceuticals (NASDAQ: KALV) gab bekannt, dass sein Vergütungsausschuss Aktienoptionen an zwölf neu eingestellte Mitarbeiter gewährt hat. Die Anreizgewährungen umfassen insgesamt 78.000 Aktien von Stammaktien zu einem Ausübungspreis von 10,61 $ pro Aktie, was dem Schlusskurs vom 1. November 2024 entspricht. Die Optionen vesten über vier Jahre, wobei 25 % nach einem Jahr und der Rest monatlich über drei Jahre vesten, vorausgesetzt, dass die Beschäftigung fortgesetzt wird. Diese Optionen mit einer Laufzeit von 10 Jahren wurden im Rahmen des Anreiz-Eigenkapitalincentiveplans von KalVista gemäß der Nasdaq-Listingregel 5635(c)(4) gewährt.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted twelve newly-hired employees inducement options to purchase an aggregate of 78,000 shares of KalVista common stock on November 1, 2024 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $10.61 per share, which was equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista’s Inducement Equity Incentive Plan and a stock option agreement covering the grant.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a global pharmaceutical company that seeks to develop and deliver oral medicines for diseases with significant unmet need. KalVista is focused on understanding the needs of patients and the limitations of current therapies to design treatments that empower people to better manage their disease and improve their lives. KalVista’s New Drug Application filing for sebetralstat for the on-demand treatment of hereditary angioedema (“HAE”) attacks has been accepted by the U.S. Food and Drug Administration with a Prescription Drug User Fee Amendments goal date of June 17, 2025. In addition, KalVista has received validation of its Market Authorization Application (“MAA”) for HAE from the European Medicines Agency and has submitted MAA applications to regulators in the United Kingdom, Switzerland, Australia, and Singapore.

For more information about KalVista, please visit www.kalvista.com or follow on social media at @KalVista and LinkedIn.

KalVista Pharmaceuticals, Inc.

Media:

Jenn Snyder

Vice President, Corporate Affairs

(857) 356-0479

jennifer.snyder@kalvista.com

Investors:

Ryan Baker

Head, Investor Relations

(617) 771-5001

ryan.baker@kalvista.com

Source: KalVista Pharmaceuticals, Inc.

FAQ

How many shares were granted in KalVista Pharmaceuticals (KALV) inducement options on November 1, 2024?

KalVista Pharmaceuticals granted inducement options for an aggregate of 78,000 shares to twelve newly-hired employees.

What is the exercise price for KALV's November 2024 inducement stock options?

The exercise price for the inducement options is $10.61 per share, equal to KalVista's closing stock price on the grant date.

What is the vesting schedule for KALV's November 2024 inducement options?

The options vest 25% after one year, with the remaining 75% vesting in equal monthly installments over the following three years, subject to continued employment.

KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

KALV Rankings

KALV Latest News

KALV Stock Data

463.27M
38.32M
1.27%
110.26%
15.9%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE